Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa

Yohei Ozawa, Kristin C. Hicks, Christine M. Minnar, Karin M. Knudson, Jeffrey Schlom, and Sofia R. Gameiro

Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA

ABSTRACT

Most monoclonal antibodies (MAbs), including immune checkpoint inhibitor MAbs, are delivered intravenously (i.v.) to patients. Recent clinical studies have demonstrated that some anti-PD1 MAbs may also be delivered subcutaneously (s.c.), with clinical outcomes similar to those obtained with i.v.-delivered agents. Bintrafusp alfa, a first-in-class bifunctional fusion protein composed of the extracellular domain of the human transforming growth factor β receptor II (TGF-βRII or TGF-β “trap”) fused to the heavy chain of an IgG1 antibody blocking programmed death ligand 1 (anti-PDL1), was designed to target two key immunosuppressive pathways in the tumor microenvironment (TME). Bintrafusp alfa is currently being administered i.v. in clinical studies. The studies reported here demonstrate that systemic or s.c. delivery of bintrafusp alfa, each administered at five different doses, induces similar anti-tumor effects in breast and colorectal carcinoma models. An interrogation of the TME for CD8+ and CD4+ T cells, regulatory T cells (Tregs), monocytic myeloid-derived suppressor cells (M-MDSCs) and granulocytic (G) MDSCs showed similar levels and phenotype of each cell subset when bintrafusp alfa was given systemically or s.c. Subcutaneous administration of bintrafusp alfa also sequestered TGFβ in the periphery at similar levels seen with systemic delivery. To our knowledge, this is the most comprehensive preclinical evaluation of any checkpoint inhibitor MAb given s.c. vs systemically, and the first to demonstrate this phenomenon using a bifunctional agent. These studies provide preclinical rationale to explore s.c. approaches for bintrafusp alfa in the clinic.

Introduction

Antibodies targeting immune checkpoints (IC), including programmed cell death 1 (PD-1) receptor and its ligand PD-L1 have achieved unprecedented clinical success in subsets of cancer patients. PD-1 is expressed on activated natural killer (NK) and T cells. PD-1 interaction with its ligands PD-L1 and PD-L2, expressed on tumor cells and multiple immune cell subsets, inhibits proliferation, maturation, and effector functions on both T lymphocytes and NK cells. PD-L1 overexpression is present in a wide spectrum of malignancies, correlating with poor prognosis. In recent years, multiple monoclonal antibodies (MAbs) targeting the PD-1/PD-L1 axis have received regulatory approval, including nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. These agents were approved for parental administration; however, the subcutaneous (s.c.) route is currently being explored in several clinical studies including the anti-PD-1 PF-06801591, and envolimab (KN035), a PD-L1-targeting nanobody. In a phase 1 open-label, multicenter, dose-escalation trial (NCT02573259), 40 patients with locally advanced or metastatic solid tumors received PF-06801591 parentally (0.5, 1, 3, or 10 mg/kg q3w) or subcutaneously (300 mg q4w). Comparable safety profile and anti-tumor activity in a variety of tumor types were observed with both s.c. and intravenous (i.v.) delivery. Collectively, these studies suggest that s.c. delivery is a more convenient and equally effective alternative to conventional parental administration of checkpoint inhibitor MAbs.

Bintrafusp alfa (previously designated M7824) is a first-in-class bifunctional fusion protein with two extracellular transforming growth factor β receptor II (TGF-βRII) domains fused to the C-terminus of a human MAb targeting the IC PD-L1. This TGFβ Trap/anti-PDL1 agent is designed to act both as a checkpoint inhibitor and to sequester "trap" TGFβ in the tumor microenvironment (TME) via anti-PDL1 delivery. Preclinical studies demonstrated its bifunctional targeting and immune-mediated mechanisms by which bintrafusp alfa promotes anti-tumor efficacy. The first-in-human trial of bintrafusp alfa, administered i.v. to patients with advanced solid malignancies, indicated a manageable safety profile and encouraging signs of clinical efficacy across all dose levels (1, 3, 10, or 20 mg/kg), with objective and durable responses. Several clinical studies examining safety and efficacy of bintrafusp alfa as monotherapy and in combination with other agents are currently ongoing for a wide range of tumors, including human papillomavirus (HPV)-
associated malignancies, and carcinomas of the breast, colon, lung, and prostate, among others. Of note, bintrafusp alfa is being administered i.v. in all ongoing clinical trials.

The i.v. administration of bintrafusp alfa as well as any other MAb is labor intensive in terms of pharmacy preparation, day hospital installation, and time and effort of healthcare professionals, all of which increase the cost of health care. More importantly, it is time-consuming and inconvenient for the patient, and prone to have clinical complications when compared to an s.c. injection. Since bintrafusp alfa is a first-in-class bifunctional agent, a comparison of systemic vs. s.c. administration of bintrafusp alfa was carried out in two distinct preclinical models to define whether any differences exist in terms of resultant anti-tumor efficacy, effects on soluble factors such as TGFβ in the periphery, and mechanistically via interrogation of multiple immune subsets and their phenotype in the TME.

Materials and methods

Tumor cell line

Murine breast (EMT6) carcinoma cells were obtained from American Type Culture Collection and maintained according to the provider’s recommendations. Murine colon carcinoma MC38 cells are as described. Cells were used at low passage numbers (5), and determined mycoplasma free (MycoAlert Mycoplasma Detection Kit, Lonza).

Reagent

Bintrafusp alfa (also known as M7824), a bifunctional fusion protein composed of two extracellular domains of TGF-βRII fused with a human IgG1 MAb targeting PD-L1, was kindly provided by EMD Serono under a Cooperative Research and Development Agreement with the National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.

Animals

Six- to ten-week-old female Balb/c or C57BL/6 were obtained from the NCI Frederick Cancer Research Facility (Frederick, MD). Mice were housed in microisolator cages under pathogen-free conditions, in accordance with Association for Assessment and Accreditation of Laboratory Animal Care guidelines. All studies were approved by the NIH Intramural Animal Care and Use Committee (IACUC).

Murine tumor studies

On day 0, EMT6 (2.5 × 10⁵) were implanted orthotopically into the mammary fat pad of Balb/c female mice. Alternatively, MC38 (3 × 10⁵) were implanted subcutaneously in the right flank of C57BL/6 female mice. When tumor volume reached 50–100 mm³ (days 7–9), mice were randomized to receive PBS (100μl, i.p.) or bintrafusp alfa (1, 2, 5, 10, or 20 mg/kg) by s.c. or intraperitoneal (i.p.) injection. Unless otherwise stated, s.c. administration was performed at a distant site (upper back) relative to the tumor. Dosing was repeated 4 days later. Survival was monitored, tumor size was measured twice weekly and tumor volume calculated as (length² × width)/2. On select studies, immune correlates were examined ex vivo 2 days after the second dose of bintrafusp alfa.

Ex-vivo analysis

Plasma collection and cytokine analysis. Peripheral blood was collected and plasma processed as previously described. Plasma TGFβ1 was quantified using the Mouse/Rat/Porcine/Canine TGF-beta 1 Quantikine ELISA Kit and by Sample Activation Kit 1 (R&D Systems) according to the manufacturer’s instructions, with a limit of detection of 35.187 pg/ml. Serum cytokines were quantified using the murine V-Plex Proinflammatory Panel 1 kit and MSEO QuickPlex SQ 120 (Meso Scale Diagnostics), according to the manufacturer’s instructions. The assay detection limit (pg/ml) is 0.04 (IFNy), 0.13 (TNFa), 0.06 (IL-5), 0.61 (IL-6), 0.94 (IL-10), and 0.24 (KC/GRO).

Detection of bintrafusp alfa in the TME. Detection of bintrafusp alfa bound to tumor immune and nonimmune cells was performed by flow cytometry using an anti-human IgG.

Flow cytometric analysis. Tumor single-cell suspensions were prepared using standard procedures as previously described. Cell counts were performed using 123 count eBeads (eBioscience). Staining of immune cells for flow cytometry was performed using the Cytofix/Cytoperm Kit (BD Biosciences) according to the manufacturer’s instructions. Antibodies used are listed in Supplementary Table 1 with matched isotypes obtained from the listed manufacturers. Data from >1 ×10⁵ cells were acquired on a BD FACSVersa or LSRII Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo Analysis Software (TreeStar). Gating strategies for the identification of cell populations are in Supplementary Table 2. All frequencies of phenotypic proteins were generated by subtracting the frequency of respective isotype, set between 1–5%.

Statistics

Statistical analysis was performed using GraphPad Prism 8 (GraphPad Software). Comparisons of data presented in bar graphs was performed by one-way ANOVA with Tukey’s multiple comparisons. Significant treatment effects on tumor growth were determined by two-way ANOVA. Survival was analyzed using Log-rank (Mantel-Cox) test. Statistical

| Table 1. EMT6 tumor cure rate and median overall survival elicited by bintrafusp alfa (20 or 10 mg/kg) administered via i.p. or s.c. injection. |
|-----------------|-----------------|-----------------|
|                | 20 mg/kg        | 10 mg/kg        |
|                 | Cures (%)       | mOS (d)         | Cures (%)       | mOS (d)         |
| PBS             | IP: 0/8 SC: 31  | IP: 0/8 SC: 31  | IP: 31 SC: 39   |
| Bintrafusp alfa | 4/8 (50%) SC: 51.5 | 4/9 (44%) SC: 52 | 3/8 (38%) SC: 49 | 3/9 (44%) SC: 43 |

IP, intraperitoneal injection; SC, subcutaneous injection; mOS (d), median overall survival in days.
Table 2. MC38 tumor cure rate and median overall survival elicited by bintrafusp alfa (20 mg/kg) administered by s.c. injection at a distant site (SC) or adjacent (SC local) to the tumor.

|          | Cures (%) | mOS (d) |
|----------|-----------|---------|
|          | IP SC SC local | IP SC SC local |
| PBS      | 0/11      | 31      |
| Bintrafusp alfa | 1/11 (9.1%) | 2/10 (20%) | 4/11 (36.4%) | 35 | 40.5 | 35 |

IP, intraperitoneal injection; SC, subcutaneous injection; mOS (d), median overall survival in days.

significance was set at $p < 0.05$, $^* p < 0.05$, $^{**} p < 0.01$, $^{***} p < 0.001$, $^{****} p < 0.0001$.

Results

**Subcutaneous administration of bintrafusp alfa induces significant anti-tumor efficacy**

In preclinical models of solid tumors, bintrafusp alfa administered i.v. intraperitoneally promotes significant tumor control as a monotherapy.\(^{10,12}\) To evaluate the effect of subcutaneous administration on anti-tumor efficacy elicited by bintrafusp alfa, Balb/C female mice were orthotopically implanted with EMT6 murine breast cancer cells on day 0. When tumors reached a volume of 50–100 mm\(^3\) (day 9), mice were randomized and treated with bintrafusp alfa (10 or 20 mg/kg) administered s.c. or i.p., or received PBS. A second dose was given on day 13 (Figure 1a). Bintrafusp alfa administered at 20 mg/kg induced significant reduction in tumor growth relative to PBS-treated controls, regardless of route of administration (Figure 1b). Subcutaneous administration at 20 mg/kg eradicated 44% (4/9) of tumors (Table 1), significantly increasing median overall survival (mOS) by 67.7% relative to PBS controls (Figure 1b, Table 1). Similarly, i.p. administration with the same dose cured 50% of mice (4/8), increasing mOS by 66.1% versus controls (Figure 1b, Table 1).

Next, we examined the effect of a lower dose administered by either route. As shown in Figure 1c, significant antitumor efficacy was also observed at 10 mg/kg, with both routes of administration resulting in tumor control of similar magnitude. Treatment with bintrafusp alfa by systemic or s.c. routes cured 38% or 44% of mice, resulting in similar mOS increases relative to PBS-treated mice, respectively (Figure 1c and Table 1). These data suggest that s.c. administration of bintrafusp alfa results in similar tumor control as systemic administration.

Next, we examined the antitumor activity of bintrafusp alfa administered by either route in a second tumor model. C57BL/6 female mice were implanted with MC38 murine colorectal cancer cells on day 0. When tumors reached a volume of 50–100 mm\(^3\) (day 10), mice were randomized and treated with PBS, or bintrafusp alfa (20 mg/kg) administered i.p., or by s.c. injection. A second dose was given on day 14 (Figure 1d). Bintrafusp alfa induced significant tumor control relative to PBS-treated controls, regardless of route of administration (Figure 1e; Table 2). This also translated into significant survival benefit irrespective of route of administration (Figure 1e).

Peritumoral (local) administration of bintrafusp alfa elicited comparable results (Table 2). These data suggest that s.c. administration of bintrafusp alfa elicits non-inferior antitumor efficacy relative to systemic administration.

To determine whether the similarity in anti-tumor efficacy would be maintained at lower doses of bintrafusp alfa, mice harboring orthotopic EMT6 tumors were treated on days 7 and 11 with 5, 2, or 1 mg/kg bintrafusp alfa given i.p. or s.c., or PBS (Figure 2a). As shown in Figure 2b, 5 mg/kg bintrafusp alfa significantly decreased tumor growth when administered i.p. or s.c., with no significant difference observed between both routes of administration. Similar results were observed with a dose of 2 mg/kg, with i.p. or s.c. administration eliciting comparable tumor control. Bintrafusp alfa administered at a dose of 1 mg/kg did not promote significant antitumor effects, regardless of route of administration. Noteworthy, no signs of toxicity, including skin reactions probed by the presence of redness and/or swelling, were observed in these studies.

**SC and systemic administration of bintrafusp alfa are equally effective in reducing plasma TGFβ1**

We next examined if either route of administration of bintrafusp alfa would result in a similar ability to sequester peripheral TGFβ. To this end, we examined plasma TGFβ1 protein level in EMT6 and MC38 tumor-bearing mice 2 days after the second dose (20 or 10 mg/kg) of bintrafusp alfa. As shown in Figure 3a, administration of 20 mg/kg to EMT6 tumor-bearing mice resulted in a significant and comparable reduction of plasma TGFβ1 with both routes of administration. Quantification of other plasma cytokines in this model indicated no significant modulation of IFNγ upon administration by either route, albeit IFNγ levels trended higher upon s.c. injection. We observed significant elevation of IL-5 after i.p. administration of bintrafusp alfa, with values trending toward significance ($p = 0.0583$) upon s.c. injection. Both routes of administration resulted in unremarkable alteration in TNFa, IL-6, IL-10, and KC/GRO (Figure 3a) in EMT6 tumor-bearing mice. Analysis of TGFβ1 and other cytokines 2 days after i.p. or s.c. administration of bintrafusp alfa at 10 mg/kg also showed no significant alteration in any cytokine level (Figure 3b), with both routes of administration eliciting similar results. In the MC38 model, analysis of plasma TGFβ1 protein levels 2 days after the second dose (20 mg/kg) of bintrafusp alfa resulted in a significant reduction of TGFβ1 irrespective of route of administration. No significant alterations were observed in protein levels of any of the additional cytokines examined with i.p. or s.c. administration (Figure 3c).

These data suggest that despite potential differences in pharmacokinetics between both routes of administration, the ability of bintrafusp alfa to sequester peripheral TGFβ1 remained similar following either route of agent administration.

**Bintrafusp alfa localizes to the tumor microenvironment after s.c. administration**

We next examined the presence of bintrafusp alfa on the surface of immune and nonimmune cell populations in the TME. On days 7 and 11 after tumor implant, EMT6 tumor-bearing
mice received PBS, or bintrafusp alfa (10 or 20 mg/kg) given i.p. or s.c. Two days after the last dose, the presence of bintrafusp alfa in the TME was examined by flow cytometry using a fluorescently labeled anti-human IgG antibody (Figure 4a).

As shown in Figure 4b (upper panel), administration of 20 mg/kg bintrafusp alfa resulted in significant and comparable binding magnitude of the bifunctional molecule to the surface of nonimmune (CD45<sup>+</sup>) cells in the TME when administered by either route. However, at the lower dose of 10 mg/kg, s.c. administration resulted in a significantly higher level of binding to nonimmune cells relative to i.p. dosing (Figure 4b, lower panel). Examining immune subsets in the TME after a dose of 20 mg/kg i.p. revealed that bintrafusp alfa was bound in significant levels to CD8<sup>+</sup> and CD4<sup>+</sup> tumor-invading lymphocytes (TILs), regulatory T cells (Tregs), and to a higher degree monocytic myeloid-derived suppressor cells (M-MDSCs) and granulocytic (G) MDSCs (Figure 4c, upper panels). Similar results at this dose level were observed with s.c. dosing, albeit a non-significant reduction in bintrafusp alfa binding to CD4<sup>+</sup> and Treg TILs was observed. At 10 mg/kg

Figure 1. Effect of bintrafusp alfa route of administration on tumor growth. (a-c) EMT6 murine breast carcinoma cells (2.5 × 10<sup>5</sup>) were implanted in the mammary fat pad of Balb/C female mice on day 0. When tumor volume reached 50–100 mm<sup>3</sup> (day 9), mice were randomized (n = 8–9/group) and treated on days 9 and 13 with PBS (100µl, i.p.), or with two different doses (20 mg/kg or 10 mg/kg) of bintrafusp alfa via i.p. or s.c. injection, as depicted in the schematic (a). Tumors were measured twice weekly using digital calipers, and tumor growth and survival were monitored. Tumor mean ± SEM growth curves, individual tumor growth curves, and survival of mice treated with 20 mg/kg (b), or 10 mg/kg (c). (d-e) MC38 murine colorectal carcinoma cells (3 × 10<sup>5</sup>) were implanted in the right flank of C57BL/6 female mice on day 0. When tumor volume reached 50–100 mm<sup>3</sup> (day 10), mice were randomized (n = 10–11/group) and treated on days 10 and 14 with PBS (100µl, i.p.) or bintrafusp alfa (20 mg/kg) via i.p. or s.c. injection, as depicted in the schematic (d). Tumors were measured twice weekly using digital calipers, and tumor growth and survival were monitored. Graphs depict tumor mean ± SEM growth curves and survival of mice (e). Mantel Cox used for survival comparisons, and two-way ANOVA for tumor growth. *p < .05, **p < .01, ***p < .001, ****p < .0001.
(Figure 4c, lower panels), s.c. administration elicited a significant presence of bintrafusp alfa bound to CD8⁺ and CD4⁺ TILs, which was not observed upon i.p. administration at this dose level. No appreciable binding to Tregs was observed with either route of administration at 10 mg/kg. However, at this dose level, both routes of administration resulted in similar and significant bintrafusp binding to both MDSC subsets, albeit a non-significant difference favoring s.c. administration. These data indicate that s.c. administration is clearly non-inferior to systemic i.p. administration in promoting the presence of bintrafusp alfa binding to immune and nonimmune cells in the TME.

Next, we examined the presence of bintrafusp alfa in the TME of MC38 tumors 2 days after the second dose (20 mg/kg) given i.p. or s.c. (Figure 4d). As shown in Figure 4e, bintrafusp alfa displayed comparable binding magnitude to the surface of nonimmune (CD45<sup>neg</sup>) cells in the TME when administered by i.p. or s.c. routes. Bintrafusp alfa (i.p.) was bound in significant levels to CD8⁺ and CD4⁺ TILs, M-MDSCs and G-MDSCs, and to a lesser extent to Tregs (Figure 4f). Subcutaneous administration elicited similar results, in addition to significant binding to Tregs. Collectively, these data indicate that s.c. dosing is non-inferior to i.p. administration in promoting the presence of bintrafusp alfa binding to immune and nonimmune cells in the TME.

Subcutaneous administration of bintrafusp alfa results in PD-L1 blockade in the tumor microenvironment similar to that obtained via systemic administration

To investigate the impact of route of administration on the ability of bintrafusp to target PD-L1 in the TME, EMT6 tumors excised 2 days after the last dose of 10 or 20 mg/kg were examined by flow cytometry for the detection of PD-L1 on the surface of immune and nonimmune cells (Figure 5a). Administration of 20 mg/kg resulted in a 4.5-fold decrease in detected PD-L1 on nonimmune/tumor cells on a per cell basis, with no significant difference observed between i.p. and s.c. administration (Figure 5b, upper panel). No significant PD-L1 blockade in CD45<sup>neg</sup> cells was observed with either route of administration at the lower dose (Figure 5b, lower panel). Administration of bintrafusp alfa at 20 mg/kg resulted in significant PD-L1 blockade on CD8⁺, CD4⁺, and Treg TILs, and both M⁺ and G-MDSCs, with i.p. and s.c. administration attaining similar magnitude of effects (Figure 5c, upper panels). Despite a lesser magnitude of PD-L1 blockade observed at 10 mg/kg, both routes of administration attained similar results, both eliciting a significant reduction of detectable PD-L1 on the surface of CD4⁺ and Treg TILs (Figure 5c, lower panels).

Next, we examined PD-L1 levels in immune and nonimmune cells in the TME of MC38 tumor-bearing mice 2 days after the last administration of bintrafusp alfa (20 mg/kg) (Figure 5d). In findings similar to those in EMT6 tumors, administration of bintrafusp alfa resulted in significant and comparable blockade of PD-L1 in both nonimmune CD45<sup>neg</sup> cells (Figure 5e) as well as in all immune subsets examined (Figure 5f) with either route of administration. Collectively,
Tukey’s (20 KC/GRO days EMT6 T administration. and fusp - these p pp). Figure e1915561-6 action on tiveative comparison, both 20 mg/kg (Figure 6). Next, we examined the impact of route of administration on the phenotype of immune cells infiltrating EMT6 and MC38 tumors 2 days after the last bintrafusp alfa dose. In prior preclinical solid tumor models, the mechanism of action of bintrafusp alfa has been shown to be mostly mediated by CD8+ T cell cytotoxicity.12,14 As shown in Figure 6, whereas neither route affected the infiltration of CD8+ T cells in EMT6 tumors upon administration of 20 mg/kg (upper panels) or 10 mg/kg (middle panels), both i.p. and s.c. administration induced a significant and comparable increase in the population of CD8+ TILs containing granzyme B with either dose. However, s.c. administration resulted in higher levels of granzyme B per CD8+ T cell (geometric mean fluorescence intensity; gMFI) in the EMT6 TME relative to i.p. dosing, with significant difference observed at the lower dose. Bintrafusp alfa did not significantly alter the infiltration of CD4+ TILs in EMT6 tumors, regardless of dose and route of administration. We observed that both i.p. and s.c. administration significantly decreased the number of Tregs in the EMT6 TME to a similar extent, resulting in similar effects on CD8/Treg ratio. Additionally, both routes of administration resulted in a similar and significant decrease in infiltration of M-MDSCs. Analysis of immune cells in MC38 tumors upon i.p. or s.c. dosing of bintrafusp alfa (20 mg/kg) elicited comparable results (Figure 6, lower panels). No significant effects were observed in tumor infiltration of CD4+ TILs, Tregs, or M-MDSCs. Similar to observations in the EMT6 model, both routes of administration resulted in a non-significant trending elevation of CD8/Treg ratio. Neither route of administration impacted the infiltration of CD8+ TILs. However, both routes of administration equally induced a significant increase in the population of CD8+ TILs containing cytolytic granzyme B. Overall, these data indicate that the immune modulatory effects and antitumor efficacy of bintrafusp alfa are not significantly different between i.p. and s.c. administration.
Discussion

In addition to immune checkpoint inhibitor MAbs, the emergence of MAbs targeting tumor-associated antigens has dramatically altered the oncology field in recent decades by significantly improving clinical responses for patients with certain malignancies.19 This led to regulatory approval of multiple agents targeting diverse antigens overexpressed in multiple malignancies, including trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive breast cancer, and rituximab for multiple CD20-expressing hematological cancers, among others.20,21 Whereas MAbs have been traditionally developed and approved to be administered i.v., various randomized clinical studies with
trastuzumab have identified s.c. administration as a viable alternative. Based on these studies, subcutaneous trastuzumab (Herceptin Hylecta®) is now approved by the Food and Drug Administration (FDA) and the European Medicines Agency as an alternative to standard parental infusion.

Clinical studies with rituximab have also compared s.c. to conventional i.v. administration, demonstrating non-inferior pharmacokinetics, and a similar safety and efficacy profile as with rituximab i.v. Based on these clinical findings, rituximab s.c. (Rituxan Hycela®) is now FDA approved for multiple indications.

To the best of our knowledge, there are no reports examining the efficacy of s.c. administration of any bifunctional agent. Previous reports have demonstrated significant antitumor activity...
efficacy of bintrafusp alfa when given systemically in multiple murine models of solid cancers, including EMT6 breast and MC38 colorectal tumors.\textsuperscript{10,12} Here, we report our preclinical findings comparing the efficacy and immune correlates of s.c. vs. systemic i.p. administration of bintrafusp alfa at multiple dose levels in the EMT6 breast tumor model, and in the MC38 colorectal tumor model. Our findings in the EMT6 model indicate no significant difference between both routes of administration in attaining antitumor efficacy, cure rate, or survival elicited by a range of doses. Similar findings were observed in MC38 tumor-bearing mice. Importantly, no signs of toxicity, including injection-site reactions, were observed with either route of administration in these studies.

We have previously reported\textsuperscript{12} that upon i.p. administration of 20 mg/kg, bintrafusp alfa was bound to a significant proportion (~40%) of nonimmune CD45\textsuperscript{-neg} cells in the TME, resulting in significant reduction in PD-L1 detection on the surface of those cells. This reduction was not observed upon administration of a mutant bintrafusp alfa devoid of PD-L1 binding ability. These findings were consistent with results from in vitro studies demonstrating bintrafusp alfa-mediated concentration-dependent decrease in PD-L1 detection on the surface of murine tumor cells at 4°C, which was not observed with mutant bintrafusp alfa.\textsuperscript{12} This strongly suggests that the reduced detection of PD-L1 elicited by bintrafusp alfa is a result of agent binding to PD-L1 as opposed to PD-L1 down-regulation or agent binding to TGFβ1 on the cell surface. Here, we extended these findings to examine the magnitude of bintrafusp alfa binding on a per cell basis on both immune and nonimmune cells present in the EMT6 and MC38 TMEs upon administration of 10 mg/kg and/or 20 mg/kg. These data indicate that bintrafusp alfa localizes to the TME when administered i.p. or s.c., with both routes resulting in similar levels of the molecule detected per cell in nonimmune cells with the highest dose. Interestingly, at the lower dose level, we observed a significantly higher localization of the agent on nonimmune cells when administered subcutaneously.

Analysis of the EMT6 TME immunome revealed extensive binding of bintrafusp alfa to both regulatory (MDSCs, Tregs), and effector (CD4, CD8) immune cell subsets, with highest levels observed in M-MDSCs, which displayed the highest level of PD-L1 expression. Significant binding was also observed in G-MDSCs and Tregs, with CD4\textsuperscript{+} and CD8\textsuperscript{+} T cells having lower levels of bound bintrafusp alfa. Notably, at the highest dose both systemic and subcutaneous administration resulted in similar extent and profile of binding, with the lowest dose (10 mg/kg) favoring s.c. administration. Despite these differences, however, both routes of administration resulted in a similar magnitude of PD-L1 blockade in both immune and nonimmune cells in the TME, as well as comparable ability of bintrafusp alfa to reduce plasma TGFβ1 levels. Similar results were observed in MC38 tumor-bearing mice.

These findings are consistent with data from several clinical studies comparing subcutaneous and intravenous administration of MAbs other than checkpoint inhibitors in cancer patients.\textsuperscript{22,23,26,28–31} This paradigm shift in the delivery platform is supported by clinical studies analyzing other important aspects of healthcare delivery, such as patient preference and
healthcare-associated costs. Multiple studies with tumor-targeted MAbs have indicated a clear and consistent patient preference for s.c. administration relative to i.v. administration.\textsuperscript{23, 24, 27, 28, 32, 34} In one example, an international clinical study of 488 patients with early breast cancer randomized to receive s.c. trastuzumab followed by i.v., or vice-versa (PrefHer study, NCT01411166), revealed consistent patient preference for s.c. (88.9%) over i.v. (9.6%) administration, with safety consistent with previous reports.\textsuperscript{23, 24, 34} Similar patient preference was observed in a randomized trial with 113 patients in the metastatic setting (MetasPHer study, NCT01810393).\textsuperscript{25} Patient preference for either route of rituximab administration was also assessed on a randomized study (PrefMab, NCT01724021) with 743 previously untreated patients with CD20\textsuperscript{+} diffuse large B-cell or follicular lymphoma. Safety was similar between both routes of administration, with 81% of patients preferring s.c. rituximab.\textsuperscript{27}

Treatment regimens with parental administration of MAbs require more frequent and longer patient visits to the clinic.\textsuperscript{32} Quantification of healthcare professional (HCP) and patient chair times in the SABRINA trial in eight countries revealed that s.c. administration resulted in significant reductions in HCP time (32%) and mean chair time (74%), potentially translating into higher efficiency of day oncology units and reduced healthcare costs.\textsuperscript{32} Thus, by reducing patient treatment time and frequency, s.c. administration may increase the efficiency of the day clinic units and reduce costs associated with treatment and loss of patient productivity, while increasing patient comfort and satisfaction.\textsuperscript{35–37}

The studies reported here provide the rationale to evaluate the delivery of bintrafusp alfa, a bifunctional agent that both targets PD-L1 and sequesters TGF\(\beta\), systemically vs s.c. injection in clinical studies to determine whether the s.c. route of administration, with its advantages described above, will attain similar clinical efficacy.

Acknowledgments
The authors recognize Curtis Randolph for his exceptional technical assistance and Debra Weingarten for her excellent assistance in the preparation of this manuscript.

Disclosure of potential conflicts of interest
The authors report no potential conflicts of interest.

Funding
This research was supported by the Intramural Research Program of the Center for Cancer Research, National Cancer Institute (NCI), National Institutes of Health [ZIA BC 010944, “Strategies for Cancer Immunotherapy Development: Preclinical Studies”], and by a Collaborative Research and Development Agreement (CRADA) between the NCI and EMD Serono, Inc., a business of Merck KGaA, Darmstadt, Germany [#02666].

ORCID
Jeffrey Schlom  http://orcid.org/0000-0001-7932-4072

Sofia R. Gameiro  http://orcid.org/0000-0002-2392-8122

References
1. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264. doi:10.1038/nrc3239.
2. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350–1355. doi:10.1126/science.aar4060.
3. Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8):1537–1544. doi:10.1182/blood-2008-12-195792.
4. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974–1982. doi:10.1200/JCO.2014.59.4358.
5. Sharpe AH, Freeman GJ. The B7–CD28 superfamily. Nat Rev Immunol. 2002;2(2):116–126. doi:10.1038/nri7277.
6. Hamaishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365. doi:10.1073/pnas.0611533104.
7. Li D, Cheng S, Zou S, Zhu D, Zhu T, Wang P, Zhu X. ImmunopET imaging of (9)Zr labeled anti-PD-L1 domain antibody. Mol Pharm. 2018;15(4):1674–1681. doi:10.1021/acs.molpharmaceut.8b00062.
8. Wu Z, Man S, Sun R, Li Z, Wu Y, Zuo D. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer. Int Immunopharmacol. 2020;85:106613. doi:10.1016/j.intimp.2020.106613.
9. Johnson ML, Braithwaite F, Grilley-Olson JE, Chou J, Davda J, Forgia A, Li R, Jacobs I, Kazazi F, Hu-Lieskovan S. Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-0681591 in patients with advanced solid tumors: a phase 1 dose-escalation trial. JAMA Oncol. 2019;5(7):999–1007. doi:10.1001/jamaoncol.2019.0836.
10. Lan Y, Zhang D, Xu C, Hance KW, Marelli B, Qi J, Yu H, Qin G, Sircar A, Hernandez VM, et al. Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-β. Sci Transl Med. 2018;10(424):424. doi:10.1126/scitranslmed.aat5488.
11. Lind H, Gameiro SR, Jochems C, Donahue RN, Strauss J, Gulley JM, Palenca C, Schlom J. Dual targeting of TGF-beta and PD-L1 via a bifunctional anti-PD-L1/TGF-betaRII agent: status of preclinical and clinical advances. J Immunother Cancer. 2020;8(1):1. doi:10.1136/jitc-2019-000433.
12. Knudson KM, Hicks KC, Luo X, Chen QJ, Schlom J, Gameiro SR. M7824, a novel bifunctional anti-PD-L1/TGFbeta Trap fusion protein, promotes anti-tumor efficacy as monotherapy and in combination with vaccine. Oncoimmunology. 2018;7(5):e1426519. doi:10.1080/2162402X.2018.1426519.
13. Grenga I, Donahue RN, Gargulak ML, Lepone LM, Roselli M, Bilusic M, Schlom J. Anti-PD-L1/TGFbetaR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis. Urol Oncol. 2018;36(3):93.e91–93.e11. doi:10.1016/j.urolonc.2017.09.027.
14. Jochems C, Tritsch SR, Pellom ST, Su Z, Soon-Shiong P, Wong HC, Gulley JL, Schlom J. Analysis of functions of an anti-PD-L1/TGFbetaR2 bispecific fusion protein (M7824). Oncotarget. 2017;8(43):75217–75231. doi:10.18632/oncotarget.20680.
15. David JM, Dominguez C, McCampbell KK, Gulley JL, Schlom J, Palena C. A novel bifunctional anti-PD-L1/TGF-beta Trap fusion protein (M7824) efficiently reverts mesenchymalization of human lung cancer cells. Oncoimmunology. 2017;6(10):e1349589. doi:10.1080/2162402x.2017.1349589.
16. Strauss J, Cr H, Schlim J, Ra M, Cao L, Kang Z, Lamping E, Jl M, Rn D, Grenga I, et al. Phase I trial of M7824 (MSB001339C), a bifunctional fusion protein targeting PD-L1 and TGFbeta, in advanced solid tumors. Clin Cancer Res. 2018;24(6):1287–1295. doi:10.1158/1078-0432.Ccr-17-2653.

17. Strauss J, Gatti-Mays ME, Cho BC, Hill A, Salas S, McClay E, Redman JM, Abdul Sater H, Donahue RN, Jochems C, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020;8(2):e001395. doi:10.1136/jitc-2020-001395.

18. Robbins PF, Kantor JA, Salgaller M, Hand PH, Fernsten PD, Schlom J. Transduction and expression of the human carcinoma-bryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 1991;51:3657–3662.

19. Weiner GJ. Building better monoclonal antibody-based therapeutics. Nat Rev Cancer. 2015;15(6):361–370. doi:10.1038/nrc3930.

20. Gatti-Mays ME, Balko JM, Gameiro SR, Bear HD, Prabhakaran S, Fukui J, Disis ML, Nanda R, Gulley JL, Kalinsky K, et al. If we build it they will come: targeting the immune response to breast cancer. NPJ Breast Cancer. 2019;5(1):37. doi:10.1038/s41523-019-0133-7.

21. Salles G, Barrett M, Fox R, Maurer J, O’Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience. Adv Ther. 2017;34(10):2232–2273. doi:10.1007/s12267-017-0612-x.

22. Ismael G, Hegg R, Muehlbauer S, Heimannz D, Lumb B, Kim S-B, Pienkowski T, Lichincheri M, Semiglavoz V, Melichar B, et al. Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. Lancet Oncol. 2012;13(9):869–878. doi:10.1016/S1470-2045(12)70239-7.

23. Pivot X, Verma S, Fallowfield L, Muller V, Lichincheri M, Jenkins V, Sanchez Munoz A, Machackova Z, Osborne S, Gligorov J, et al. Efficacy and safety of subcutaneous trastuzumab and intravenous trastuzumab as part of adjuvant therapy for HER2-positive early breast cancer: final analysis of the randomised, two-cohort PreHer study. Eur J Cancer. 2017;86:82–90. doi:10.1016/j.ejca.2017.08.019.

24. Gligorov J, Curigliano G, Muller V, Knoop A, Jenkins V, Verma S, Osborne S, Lauer S, Machackova Z, Fallowfield L, et al. Switching between intravenous and subcutaneous trastuzumab: safety results from the PreHer trial. Breast. 2017;34:89–95. doi:10.1016/j.breast.2017.05.004.

25. Pivot X, Spano JP, Espie M, Cottu P, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, et al. Patients’ preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: results of the randomised MetasphHer study. Eur J Cancer. 2017;82:230–236. doi:10.1016/j.ejca.2017.05.009.

26. Davies A, Merli F, Mihaljevic B, Mercadal S, Siritanaratkul N, Solal-Celigny P, Boehnke A, Berge C, Genevray M, Zharkov A, et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial. Lancet Haematol. 2017;4(6):e272–e282. doi:10.1016/S2352-3026(17)30078-9.

27. Rummel M, Kim TM, Aversa F, Brugger W, Capochiani E, Plenteda C, Re F, Trask P, Osborne S, Smith R, et al. Preference for subcutaneous or intravenous administration of rituximab among patients with untreated CD20+ diffuse large B-cell lymphoma or follicular lymphoma: results from a prospective, randomised, open-label, crossover study (PreFimb). Ann Oncol. 2017;28(4):836–842. doi:10.1093/annonc/mdw685.

28. Chen L, Diao L, Yang Y, Yi X, Rodriguez BL, Li Y, Villalobos PA, Cascone T, Liu X, Tan L, et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 2018;8(9):1156–1175. doi:10.1158/2159-2890.CD-17-1033.

29. Jackisch C, Stroyakovskiy D, Pivot X, Ahn JS, Melichar B, Chen S-C, Meyenberg C, Al-Sakkaf N, Heimannz D, Hegg R. Subcutaneous vs intravenous trastuzumab for patients with ERBB2-positive early breast cancer: final analysis of the HannaH phase 3 randomised clinical trial. JAMA Oncol. 2019;5(5):e190339. doi:10.1001/jamaoncol.2019.0339.

30. Mateos M-V, Nahi H, Legiec W, Grosicki S, Vorobyev V, Spicka I, Hungria V, Korenkova S, Bathis N, Flogfegard M, et al. Subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma (COLUMBA): a multicentre, open-label, non-inferiority, randomised, phase 3 trial. Lancet Haematol. 2020;7(5):e370–e380. doi:10.1016/S2352-3026(20)30070-3.

31. Usmani SZ, Nahi H, Mateos M-V, Van De Donk N, Chari A, Kaufman JL, Moreau P, Oriol A, Plesner T, Benoubker L, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.2019000667.

32. De Cock E, Kritikou P, Sandoval M, Tao S, Wiesner C, Carella AM, Ngoth C, Waterboer T, Borrow R. Time savings with rituximab subcutaneous injection versus rituximab intravenous infusion: a time and motion study in eight countries. PLoS One. 2016;11(6):e0157957. doi:10.1371/journal.pone.0157957.

33. Pivot X, Gligorov J, Muller V, Curigliano G, Knoop A, Verma S, Jenkins V, Scotto N, Osborne S, Fallowfield L, et al. Patients’ preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomised, two-cohort PreHer study. Ann Oncol. 2014;25(10):1979–1987. doi:10.1093/annonc/mdu364.

34. Pivot X, Gligorov J, Muller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglavoz V, Lopez-Vivanco G, Jenkins V, et al. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PreHer): an open-label randomised study. Lancet Oncol. 2013;14(10):962–970. doi:10.1016/S1470-2045(13)70383-8.

35. Lopez-Vivanco G, Salvador J, Diez R, Lopez D, De Salas-Cansado M, Navarro B, De La Haba-rodriguez J. Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain. Clin Transl Oncol. 2017;19(12):1454–1461. doi:10.1007/s12094-017-1684-4.

36. Olofsson S, Norrild H, Karlsson E, Wilking U, Ragnarsson Tennvall G. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer – an observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140–146. doi:10.1016/j.breast.2016.07.008.

37. North RT, Harvey VJ, Cox LC, Ryan SN. Medical resource utilization for administration of trastuzumab in a New Zealand oncology outpatient setting: a time and motion study.. Clinicoecon Outcomes Res. 2015;7:423–430. doi:10.2147/CEOR.S85599.